{"success":true,"data":{"pressRelease":{"id":"129351","rtpr_id":"nGNX6C3W12","ticker":"PPCB","exchange":"NASDAQ","all_tickers":["PPCB"],"title":"Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit","author":"Globe Newswire","published_at":"2026-08-27T12:30:00.460Z","article_body":"MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma,\nInc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical\ncompany focused on developing novel treatments for chronic diseases, including\nrecurrent and metastatic cancer, today announced compelling new preclinical\nand early translational data for its lead candidate PRP in pancreatic ductal\nadenocarcinoma (PDAC).\n\nIn orthotopic and patient-derived xenograft (PDX) models of advanced PDAC,\nthree-times-weekly intravenous PRP achieved:\n* Greater than 90%, mean, tumor growth inhibition versus vehicle controls (p <\n0.001).\n* Marked reduction in metastatic burden in the liver and peritoneum.\n* Significant remodeling of the tumor microenvironment, including decreased\ncancer-associated fibroblast activity, reduced fibrosis, and suppression of\nepithelial-mesenchymal transition (EMT) markers.\n* Enhanced sensitivity of chemo-resistant PDAC cells to standard-of-care\ngemcitabine/nab-paclitaxel, supporting lower chemotherapy doses with improved\nefficacy.\n* Median overall survival extension of more than 2.5-fold in treated animals\ncompared with controls.\nThese results were built on previously reported >85% tumor growth inhibition\ndata and peer-reviewed findings on PRP’s effects on PDAC fibroblasts.\nLimited prior compassionate-use experience with related proenzyme formulations\nhas shown signals of prolonged survival in advanced solid-tumor patients with\na favorable safety profile and no severe treatment-related adverse events.\n\nComparison to Revolution Medicines Clinical Data\n\nRevolution Medicines’ multi-selective RAS(ON) inhibitor daraxonrasib\nrecently delivered practice-changing Phase 3 results (RASolute 302) in\npreviously treated metastatic PDAC. In that trial of approximately 500\npatients, daraxonrasib achieved median overall survival of 13.2 months versus\n6.6–6.7 months with chemotherapy (hazard ratio 0.40; ~60% reduction in risk\nof death), median progression-free survival of 7.2–7.3 months versus\n3.5–3.6 months, and objective response rates of approximately 32% versus\n11%.\n\nWhile these clinical outcomes represent a major advance for RAS-mutant disease\n(present in ~90% of PDAC cases), PRP operates through a fundamentally\ndifferent mechanism. PRP is a proprietary fixed-ratio combination of the two\npancreatic proenzymes, trypsinogen and chymotrypsinogen. It promotes\ndifferentiation of malignant cells toward a more normal phenotype, reverses\nEMT, targets cancer stem cells, suppresses metastasis and angiogenesis, and\nremodels the supportive tumor microenvironment—without relying on cytotoxic\npathway inhibition.\n\nPropanc believes this non-cytotoxic, differentiation-based approach addresses\nkey drivers of resistance, recurrence, and dissemination that persist even\nafter RAS pathway blockade. PRP holds FDA Orphan Drug Designation for\npancreatic cancer and is not limited to specific RAS mutations, supporting\npotential broad applicability across solid tumors and possible use in\ncombination or sequential settings with RAS inhibitors or standard\nchemotherapy.\n\n“Pancreatic cancer remains one of oncology’s greatest challenges, with\nfive-year survival rates still near 13% and limited durable options for\npatients with metastatic disease,” said James Nathanielsz, Chief Executive\nOfficer of Propanc. “The recent clinical progress with RAS(ON) inhibitors\nsuch as daraxonrasib is tremendously exciting. Our new data reinforce PRP’s\ndifferentiated mechanism—targeting cancer stem cells, disrupting the\nfibrotic microenvironment, and potentially overcoming resistance—and give us\nstrong conviction as we advance into the clinic. We are accelerating our Phase\n1b First-in-Human study in advanced solid tumors, with pancreatic cancer as a\nkey focus indication.”\n\nThe Company is progressing GMP manufacturing, pharmacokinetics assay\nvalidation, and clinical partnerships in support of a planned Phase 1b study\nin approximately 40 – 45 patients with advanced solid tumors. A clinical\ntrial application is expected in the coming months.\n\nAbout Propanc Biopharma, Inc.\n\nPropanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to\npreventing cancer recurrence and metastasis by targeting and eradicating\ncancer stem cells through proenzyme activation. The Company’s lead product\ncandidate, PRP, is designed to address the underlying drivers of cancer\nproliferation and spread.\n\nMore information: www.propanc.com\n\nForward-Looking Statements\n\nAll statements in this press release that are not historical are\nforward-looking statements, including, among other things, statements relating\nto the Company’s expectations regarding its market position and market\nopportunity, expectations and plans as to its product development,\nmanufacturing and sales, and relations with its partners and investors, made\nin reliance upon the safe harbor provisions of Section 27A of the Securities\nAct of 1933, as amended, and Section 21E of the Securities Exchange Act of\n1934, as amended. These statements are not historical facts but rather are\nbased on the Company’s current expectations, estimates, and projections\nregarding its business, operations and other similar or related factors. Words\nsuch as “may,” “will,” “could,” “would,” “should,”\n“anticipate,” “predict,” “potential,” “continue,”\n“expect,” “intend,” “plan,” “project,” “believe,”\n“estimate,” and other similar or related expressions are used to identify\nthese forward-looking statements, although not all forward-looking statements\ncontain these words. You should not place undue reliance on forward-looking\nstatements because they involve known and unknown risks, uncertainties, and\nassumptions that are difficult or impossible to predict and, in some cases,\nbeyond the Company’s control. Forward-looking statements are not guarantees\nof future actions or performance. Actual results may differ materially from\nthose in the forward-looking statements because of several factors, including,\nwithout limitation, risks and uncertainties related to market conditions, as\nwell as those risks described under “Risk Factors” in the prospectus\nrelated to the proposed offering and those described in the Company’s\nfilings with the SEC. The Company undertakes no obligation to revise or update\ninformation in this release to reflect events or circumstances in the future,\neven if new information becomes available.\n\nCompany:\nPropanc Biopharma, Inc.\nJames Nathanielsz\n\n+61-3-9882-0780\n\ninfo@propanc.com\n\nInvestor Contact:\n\nirteam@propanc.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0de2a486-4708-45bf-a406-f462ad395dec)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6C3W12","title":"Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit","author":"Globe Newswire","ticker":"PPCB","created":"2026-08-27T12:30:00.460Z","tickers":["PPCB"],"exchange":"NASDAQ","article_body":"MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma,\nInc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical\ncompany focused on developing novel treatments for chronic diseases, including\nrecurrent and metastatic cancer, today announced compelling new preclinical\nand early translational data for its lead candidate PRP in pancreatic ductal\nadenocarcinoma (PDAC).\n\nIn orthotopic and patient-derived xenograft (PDX) models of advanced PDAC,\nthree-times-weekly intravenous PRP achieved:\n* Greater than 90%, mean, tumor growth inhibition versus vehicle controls (p <\n0.001).\n* Marked reduction in metastatic burden in the liver and peritoneum.\n* Significant remodeling of the tumor microenvironment, including decreased\ncancer-associated fibroblast activity, reduced fibrosis, and suppression of\nepithelial-mesenchymal transition (EMT) markers.\n* Enhanced sensitivity of chemo-resistant PDAC cells to standard-of-care\ngemcitabine/nab-paclitaxel, supporting lower chemotherapy doses with improved\nefficacy.\n* Median overall survival extension of more than 2.5-fold in treated animals\ncompared with controls.\nThese results were built on previously reported >85% tumor growth inhibition\ndata and peer-reviewed findings on PRP’s effects on PDAC fibroblasts.\nLimited prior compassionate-use experience with related proenzyme formulations\nhas shown signals of prolonged survival in advanced solid-tumor patients with\na favorable safety profile and no severe treatment-related adverse events.\n\nComparison to Revolution Medicines Clinical Data\n\nRevolution Medicines’ multi-selective RAS(ON) inhibitor daraxonrasib\nrecently delivered practice-changing Phase 3 results (RASolute 302) in\npreviously treated metastatic PDAC. In that trial of approximately 500\npatients, daraxonrasib achieved median overall survival of 13.2 months versus\n6.6–6.7 months with chemotherapy (hazard ratio 0.40; ~60% reduction in risk\nof death), median progression-free survival of 7.2–7.3 months versus\n3.5–3.6 months, and objective response rates of approximately 32% versus\n11%.\n\nWhile these clinical outcomes represent a major advance for RAS-mutant disease\n(present in ~90% of PDAC cases), PRP operates through a fundamentally\ndifferent mechanism. PRP is a proprietary fixed-ratio combination of the two\npancreatic proenzymes, trypsinogen and chymotrypsinogen. It promotes\ndifferentiation of malignant cells toward a more normal phenotype, reverses\nEMT, targets cancer stem cells, suppresses metastasis and angiogenesis, and\nremodels the supportive tumor microenvironment—without relying on cytotoxic\npathway inhibition.\n\nPropanc believes this non-cytotoxic, differentiation-based approach addresses\nkey drivers of resistance, recurrence, and dissemination that persist even\nafter RAS pathway blockade. PRP holds FDA Orphan Drug Designation for\npancreatic cancer and is not limited to specific RAS mutations, supporting\npotential broad applicability across solid tumors and possible use in\ncombination or sequential settings with RAS inhibitors or standard\nchemotherapy.\n\n“Pancreatic cancer remains one of oncology’s greatest challenges, with\nfive-year survival rates still near 13% and limited durable options for\npatients with metastatic disease,” said James Nathanielsz, Chief Executive\nOfficer of Propanc. “The recent clinical progress with RAS(ON) inhibitors\nsuch as daraxonrasib is tremendously exciting. Our new data reinforce PRP’s\ndifferentiated mechanism—targeting cancer stem cells, disrupting the\nfibrotic microenvironment, and potentially overcoming resistance—and give us\nstrong conviction as we advance into the clinic. We are accelerating our Phase\n1b First-in-Human study in advanced solid tumors, with pancreatic cancer as a\nkey focus indication.”\n\nThe Company is progressing GMP manufacturing, pharmacokinetics assay\nvalidation, and clinical partnerships in support of a planned Phase 1b study\nin approximately 40 – 45 patients with advanced solid tumors. A clinical\ntrial application is expected in the coming months.\n\nAbout Propanc Biopharma, Inc.\n\nPropanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to\npreventing cancer recurrence and metastasis by targeting and eradicating\ncancer stem cells through proenzyme activation. The Company’s lead product\ncandidate, PRP, is designed to address the underlying drivers of cancer\nproliferation and spread.\n\nMore information: www.propanc.com\n\nForward-Looking Statements\n\nAll statements in this press release that are not historical are\nforward-looking statements, including, among other things, statements relating\nto the Company’s expectations regarding its market position and market\nopportunity, expectations and plans as to its product development,\nmanufacturing and sales, and relations with its partners and investors, made\nin reliance upon the safe harbor provisions of Section 27A of the Securities\nAct of 1933, as amended, and Section 21E of the Securities Exchange Act of\n1934, as amended. These statements are not historical facts but rather are\nbased on the Company’s current expectations, estimates, and projections\nregarding its business, operations and other similar or related factors. Words\nsuch as “may,” “will,” “could,” “would,” “should,”\n“anticipate,” “predict,” “potential,” “continue,”\n“expect,” “intend,” “plan,” “project,” “believe,”\n“estimate,” and other similar or related expressions are used to identify\nthese forward-looking statements, although not all forward-looking statements\ncontain these words. You should not place undue reliance on forward-looking\nstatements because they involve known and unknown risks, uncertainties, and\nassumptions that are difficult or impossible to predict and, in some cases,\nbeyond the Company’s control. Forward-looking statements are not guarantees\nof future actions or performance. Actual results may differ materially from\nthose in the forward-looking statements because of several factors, including,\nwithout limitation, risks and uncertainties related to market conditions, as\nwell as those risks described under “Risk Factors” in the prospectus\nrelated to the proposed offering and those described in the Company’s\nfilings with the SEC. The Company undertakes no obligation to revise or update\ninformation in this release to reflect events or circumstances in the future,\neven if new information becomes available.\n\nCompany:\nPropanc Biopharma, Inc.\nJames Nathanielsz\n\n+61-3-9882-0780\n\ninfo@propanc.com\n\nInvestor Contact:\n\nirteam@propanc.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0de2a486-4708-45bf-a406-f462ad395dec)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-27T12:30:00.50873075Z","server_sent_at_ms":1787833800508},"received_at":"2026-08-27T12:30:00.558Z","source_url":"https://www.globenewswire.com/news-release/2026/08/27/3352011/0/en/propanc-biopharma-announces-compelling-new-preclinical-pancreatic-cancer-data-for-prp-showing-90-tumor-growth-inhibition-and-2-5-fold-survival-benefit.html"},"analysis":{"id":"118266","press_release_id":"129351","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Data is preclinical; translation to human efficacy remains uncertain","Release compares preclinical results directly to competitor's Phase 3 clinical data"],"eventType":"operations_update","narrative":"Propanc Biopharma reported preclinical data for its lead candidate PRP in pancreatic ductal adenocarcinoma, demonstrating greater than 90% tumor growth inhibition and a median overall survival extension of more than 2.5-fold.\n\nThe data indicated PRP remodels the tumor microenvironment and enhances sensitivity to standard-of-care chemotherapy, supporting its non-cytotoxic differentiation mechanism.\n\nThe company holds FDA Orphan Drug Designation for PRP and expects to file a clinical trial application for a Phase 1b study in advanced solid tumors in the coming months.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"PRP shows >90% tumor inhibition in preclinical pancreatic cancer models; Phase 1b filing imminent."},"keyFigures":{"drugName":"PRP","phaseOfTrial":"Phase 1b","customDimensions":{"p_value":"<0.001","planned_patients":"40-45","survival_benefit":">2.5-fold","tumor_growth_inhibition":">90%"}},"quotedText":"Our new data reinforce PRP’s differentiated mechanism—targeting cancer stem cells, disrupting the fibrotic microenvironment, and potentially overcoming resistance—and give us strong conviction as we advance into the clinic.","namedEntities":{"people":[{"name":"James Nathanielsz","role":"Chief Executive Officer"}],"products":["PRP","daraxonrasib","gemcitabine","nab-paclitaxel"],"companies":[{"name":"Propanc Biopharma, Inc.","ticker":"PPCB"},{"name":"Revolution Medicines"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Strong preclinical efficacy metrics for lead candidate PRP, but preclinical data carries high translational risk and is a routine milestone for early-stage biotechs."},"tickerRelevance":{"others":[],"primary":"PPCB"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro_cap","eventGravity":"preclinical_data"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Propanc Biopharma reported preclinical data for its lead candidate PRP in pancreatic ductal adenocarcinoma, demonstrating greater than 90% tumor growth inhibition and a median overall survival extension of more than 2.5-fold.\n\nThe data indicated PRP remodels the tumor microenvironment and enhances sensitivity to standard-of-care chemotherapy, supporting its non-cytotoxic differentiation mechanism.\n\nThe company holds FDA Orphan Drug Designation for PRP and expects to file a clinical trial application for a Phase 1b study in advanced solid tumors in the coming months.","key_figures":{"drugName":"PRP","phaseOfTrial":"Phase 1b","customDimensions":{"p_value":"<0.001","planned_patients":"40-45","survival_benefit":">2.5-fold","tumor_growth_inhibition":">90%"}},"named_entities":{"people":[{"name":"James Nathanielsz","role":"Chief Executive Officer"}],"products":["PRP","daraxonrasib","gemcitabine","nab-paclitaxel"],"companies":[{"name":"Propanc Biopharma, Inc.","ticker":"PPCB"},{"name":"Revolution Medicines"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-27T13:30:27.085Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"micro_cap","eventGravity":"preclinical_data"}},"durationMs":189305,"modelName":"glm-4.7"}}